nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—CYP2C8—Vismodegib—skin cancer	0.124	0.232	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Vismodegib—skin cancer	0.0863	0.162	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Temozolomide—skin cancer	0.0724	0.136	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Imiquimod—skin cancer	0.0724	0.136	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vismodegib—skin cancer	0.0502	0.0942	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Fluorouracil—skin cancer	0.044	0.0825	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vemurafenib—skin cancer	0.0397	0.0744	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Fluorouracil—skin cancer	0.0307	0.0575	CbGbCtD
Medroxyprogesterone Acetate—AR—scrotum—skin cancer	0.0161	0.161	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Docetaxel—skin cancer	0.0136	0.0255	CbGbCtD
Medroxyprogesterone Acetate—SHBG—hindlimb—skin cancer	0.00763	0.0765	CbGeAlD
Medroxyprogesterone Acetate—AR—penis—skin cancer	0.00725	0.0727	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—female reproductive system—skin cancer	0.00416	0.0417	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—nipple—skin cancer	0.00351	0.0351	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—head—skin cancer	0.00347	0.0348	CbGeAlD
Medroxyprogesterone Acetate—PGR—blood vessel—skin cancer	0.00328	0.0329	CbGeAlD
Medroxyprogesterone Acetate—SHBG—neck—skin cancer	0.00261	0.0261	CbGeAlD
Medroxyprogesterone Acetate—ESR1—blood vessel—skin cancer	0.00257	0.0257	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—lymph node—skin cancer	0.00243	0.0244	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—nerve—skin cancer	0.00241	0.0242	CbGeAlD
Medroxyprogesterone Acetate—PGR—nipple—skin cancer	0.00237	0.0238	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—mammalian vulva—skin cancer	0.00205	0.0205	CbGeAlD
Medroxyprogesterone Acetate—AR—nipple—skin cancer	0.00189	0.019	CbGeAlD
Medroxyprogesterone Acetate—SHBG—connective tissue—skin cancer	0.00187	0.0187	CbGeAlD
Medroxyprogesterone Acetate—ESR1—neck—skin cancer	0.00184	0.0184	CbGeAlD
Medroxyprogesterone Acetate—PGR—connective tissue—skin cancer	0.00168	0.0169	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—Corticotropin-releasing hormone—KRT14—skin cancer	0.00161	0.0808	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—epithelium—skin cancer	0.0016	0.016	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—nipple—skin cancer	0.00137	0.0137	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—neck—skin cancer	0.00136	0.0136	CbGeAlD
Medroxyprogesterone Acetate—AR—connective tissue—skin cancer	0.00134	0.0134	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female reproductive system—skin cancer	0.00132	0.0132	CbGeAlD
Medroxyprogesterone Acetate—ESR1—connective tissue—skin cancer	0.00132	0.0132	CbGeAlD
Medroxyprogesterone Acetate—AR—epithelium—skin cancer	0.00127	0.0128	CbGeAlD
Medroxyprogesterone Acetate—ESR1—epithelium—skin cancer	0.00125	0.0125	CbGeAlD
Medroxyprogesterone Acetate—PGR—lymphoid tissue—skin cancer	0.00123	0.0123	CbGeAlD
Medroxyprogesterone Acetate—AR—skin of body—skin cancer	0.00121	0.0121	CbGeAlD
Medroxyprogesterone Acetate—PGR—female reproductive system—skin cancer	0.00119	0.0119	CbGeAlD
Medroxyprogesterone Acetate—AR—mammalian vulva—skin cancer	0.0011	0.0111	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lymph node—skin cancer	0.00103	0.0103	CbGeAlD
Medroxyprogesterone Acetate—PGR—head—skin cancer	0.000992	0.00994	CbGeAlD
Medroxyprogesterone Acetate—AR—lymphoid tissue—skin cancer	0.000981	0.00983	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—connective tissue—skin cancer	0.000971	0.00974	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymphoid tissue—skin cancer	0.000963	0.00965	CbGeAlD
Medroxyprogesterone Acetate—AR—female reproductive system—skin cancer	0.000946	0.00948	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female reproductive system—skin cancer	0.000929	0.00931	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—epithelium—skin cancer	0.000922	0.00925	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—skin of body—skin cancer	0.000877	0.00879	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—KRT17—skin cancer	0.000816	0.0408	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—mammalian vulva—skin cancer	0.0008	0.00802	CbGeAlD
Medroxyprogesterone Acetate—AR—head—skin cancer	0.00079	0.00792	CbGeAlD
Medroxyprogesterone Acetate—ESR1—head—skin cancer	0.000776	0.00778	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—female reproductive system—skin cancer	0.000765	0.00767	CbGeAlD
Medroxyprogesterone Acetate—PGR—Ovarian Infertility Genes—MLH1—skin cancer	0.000723	0.0362	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—lymphoid tissue—skin cancer	0.00071	0.00712	CbGeAlD
Medroxyprogesterone Acetate—PGR—lymph node—skin cancer	0.000695	0.00696	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—female reproductive system—skin cancer	0.000685	0.00687	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—female reproductive system—skin cancer	0.000679	0.00681	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—skin cancer	0.000645	0.0323	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000585	0.0293	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—head—skin cancer	0.000572	0.00574	CbGeAlD
Medroxyprogesterone Acetate—AR—lymph node—skin cancer	0.000553	0.00555	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—skin cancer	0.000543	0.00545	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—female reproductive system—skin cancer	0.000518	0.00519	CbGeAlD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—MITF—skin cancer	0.000459	0.023	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—FOXA1 transcription factor network—SHH—skin cancer	0.000445	0.0223	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—KRT5—skin cancer	0.000429	0.0215	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—ASIP—skin cancer	0.000428	0.0214	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—XRCC1—skin cancer	0.000427	0.0214	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Endoderm Differentiation—NKX2-1—skin cancer	0.000413	0.0207	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—lymph node—skin cancer	0.000401	0.00402	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—KRT14—skin cancer	0.000399	0.0199	CbGpPWpGaD
Medroxyprogesterone Acetate—SHBG—Nongenotropic Androgen signaling—HRAS—skin cancer	0.000377	0.0189	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Ovarian Infertility Genes—CDK4—skin cancer	0.000368	0.0184	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Corticotropin-releasing hormone—BRAF—skin cancer	0.000359	0.0179	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000353	0.0177	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—FOXA1 transcription factor network—SHH—skin cancer	0.000343	0.0172	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—skin cancer	0.000308	0.0154	CbGpPWpGaD
Medroxyprogesterone Acetate—Malaise—Bleomycin—skin cancer	0.000287	0.000825	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Temozolomide—skin cancer	0.000286	0.000823	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—skin cancer	0.000285	0.0143	CbGpPWpGaD
Medroxyprogesterone Acetate—Haemoglobin—Fluorouracil—skin cancer	0.000285	0.000821	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Fluorouracil—skin cancer	0.000284	0.000817	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Vemurafenib—skin cancer	0.000283	0.000815	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Fluorouracil—skin cancer	0.000282	0.000811	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Temozolomide—skin cancer	0.000279	0.000805	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Docetaxel—skin cancer	0.000278	0.000802	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Temozolomide—skin cancer	0.000278	0.000801	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Temozolomide—skin cancer	0.000278	0.000799	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Temozolomide—skin cancer	0.000276	0.000796	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Dactinomycin—skin cancer	0.000275	0.000792	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—XRCC3—skin cancer	0.000274	0.0137	CbGpPWpGaD
Medroxyprogesterone Acetate—Anaemia—Dactinomycin—skin cancer	0.000274	0.000789	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Vemurafenib—skin cancer	0.000272	0.000784	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Temozolomide—skin cancer	0.000272	0.000784	CcSEcCtD
Medroxyprogesterone Acetate—Dry skin—Docetaxel—skin cancer	0.000271	0.000782	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Bleomycin—skin cancer	0.000271	0.000779	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Bleomycin—skin cancer	0.000271	0.000779	CcSEcCtD
Medroxyprogesterone Acetate—Orthostatic hypotension—Docetaxel—skin cancer	0.00027	0.000779	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Vemurafenib—skin cancer	0.00027	0.000777	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Temozolomide—skin cancer	0.00027	0.000777	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Vemurafenib—skin cancer	0.00027	0.000777	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Imiquimod—skin cancer	0.000269	0.000775	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Vemurafenib—skin cancer	0.000268	0.000772	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Temozolomide—skin cancer	0.000268	0.000772	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Temozolomide—skin cancer	0.000268	0.000772	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Docetaxel—skin cancer	0.000268	0.000771	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Bleomycin—skin cancer	0.000267	0.00077	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Dactinomycin—skin cancer	0.000267	0.00077	CcSEcCtD
Medroxyprogesterone Acetate—Cramp muscle—Docetaxel—skin cancer	0.000267	0.000768	CcSEcCtD
Medroxyprogesterone Acetate—Nasopharyngitis—Docetaxel—skin cancer	0.000265	0.000762	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Temozolomide—skin cancer	0.000263	0.000756	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Imiquimod—skin cancer	0.000262	0.000754	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Bleomycin—skin cancer	0.000262	0.000753	CcSEcCtD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000261	0.000752	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Bleomycin—skin cancer	0.000259	0.000747	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Bleomycin—skin cancer	0.000259	0.000747	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Temozolomide—skin cancer	0.000259	0.000747	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—PLIN2—skin cancer	0.000259	0.013	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Imiquimod—skin cancer	0.000258	0.000744	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Bleomycin—skin cancer	0.000258	0.000742	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Docetaxel—skin cancer	0.000256	0.000737	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Vemurafenib—skin cancer	0.000254	0.000732	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Bleomycin—skin cancer	0.000254	0.000731	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Dactinomycin—skin cancer	0.000252	0.000727	CcSEcCtD
Medroxyprogesterone Acetate—Bronchospasm—Docetaxel—skin cancer	0.000252	0.000725	CcSEcCtD
Medroxyprogesterone Acetate—Tremor—Temozolomide—skin cancer	0.000251	0.000723	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Fluorouracil—skin cancer	0.000251	0.000722	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Imiquimod—skin cancer	0.00025	0.00072	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Dactinomycin—skin cancer	0.000249	0.000718	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Temozolomide—skin cancer	0.000249	0.000716	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Estrogen signaling pathway—BRAF—skin cancer	0.000249	0.0124	CbGpPWpGaD
Medroxyprogesterone Acetate—Anaemia—Temozolomide—skin cancer	0.000248	0.000714	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Bleomycin—skin cancer	0.000247	0.000712	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Fluorouracil—skin cancer	0.000247	0.000711	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Temozolomide—skin cancer	0.000246	0.00071	CcSEcCtD
Medroxyprogesterone Acetate—Angioedema—Temozolomide—skin cancer	0.000245	0.000706	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Bleomycin—skin cancer	0.000242	0.000698	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Dactinomycin—skin cancer	0.000242	0.000697	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Temozolomide—skin cancer	0.000242	0.000696	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Imiquimod—skin cancer	0.000241	0.000695	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Temozolomide—skin cancer	0.000241	0.000694	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Dactinomycin—skin cancer	0.00024	0.000692	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Temozolomide—skin cancer	0.000237	0.000682	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Dactinomycin—skin cancer	0.000237	0.000682	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000236	0.000681	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Arachidonic acid metabolism—PTGS2—skin cancer	0.000233	0.0117	CbGpPWpGaD
Medroxyprogesterone Acetate—Paraesthesia—Bleomycin—skin cancer	0.000233	0.000671	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Docetaxel—skin cancer	0.000233	0.000671	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Temozolomide—skin cancer	0.000232	0.000669	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Imiquimod—skin cancer	0.000232	0.000669	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Docetaxel—skin cancer	0.000232	0.000667	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Bleomycin—skin cancer	0.000231	0.000666	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Dactinomycin—skin cancer	0.000231	0.000664	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Imiquimod—skin cancer	0.00023	0.000663	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Imiquimod—skin cancer	0.00023	0.000662	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Imiquimod—skin cancer	0.000229	0.000659	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Fluorouracil—skin cancer	0.000228	0.000658	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Temozolomide—skin cancer	0.000228	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Temozolomide—skin cancer	0.000228	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Docetaxel—skin cancer	0.000228	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Docetaxel—skin cancer	0.000228	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Temozolomide—skin cancer	0.000227	0.000655	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000227	0.000653	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Temozolomide—skin cancer	0.000226	0.00065	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Bleomycin—skin cancer	0.000226	0.000649	CcSEcCtD
Medroxyprogesterone Acetate—Acute coronary syndrome—Docetaxel—skin cancer	0.000225	0.000648	CcSEcCtD
Medroxyprogesterone Acetate—Myocardial infarction—Docetaxel—skin cancer	0.000224	0.000644	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Docetaxel—skin cancer	0.000224	0.000644	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Temozolomide—skin cancer	0.000223	0.000643	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—FOXO4—skin cancer	0.000223	0.0112	CbGpPWpGaD
Medroxyprogesterone Acetate—Jaundice—Docetaxel—skin cancer	0.000222	0.00064	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Docetaxel—skin cancer	0.000222	0.00064	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Temozolomide—skin cancer	0.000221	0.000635	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00022	0.000635	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Temozolomide—skin cancer	0.000219	0.00063	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Temozolomide—skin cancer	0.000219	0.00063	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Temozolomide—skin cancer	0.000217	0.000626	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Imiquimod—skin cancer	0.000217	0.000625	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Docetaxel—skin cancer	0.000216	0.000621	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Docetaxel—skin cancer	0.000215	0.00062	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Temozolomide—skin cancer	0.000215	0.000618	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Temozolomide—skin cancer	0.000214	0.000617	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Fluorouracil—skin cancer	0.000214	0.000616	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Bleomycin—skin cancer	0.000214	0.000616	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Temozolomide—skin cancer	0.000213	0.000612	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Temozolomide—skin cancer	0.000212	0.000609	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—XRCC3—skin cancer	0.000211	0.0106	CbGpPWpGaD
Medroxyprogesterone Acetate—Chest pain—Fluorouracil—skin cancer	0.00021	0.000606	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Fluorouracil—skin cancer	0.00021	0.000606	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Dactinomycin—skin cancer	0.00021	0.000606	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Dactinomycin—skin cancer	0.000209	0.000601	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Temozolomide—skin cancer	0.000209	0.000601	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Fluorouracil—skin cancer	0.000208	0.000598	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Bleomycin—skin cancer	0.000206	0.000593	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Docetaxel—skin cancer	0.000206	0.000593	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Bleomycin—skin cancer	0.000205	0.000591	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Docetaxel—skin cancer	0.000205	0.00059	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Docetaxel—skin cancer	0.000205	0.00059	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Fluorouracil—skin cancer	0.000203	0.000585	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Docetaxel—skin cancer	0.000203	0.000585	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Docetaxel—skin cancer	0.000202	0.000583	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Docetaxel—skin cancer	0.000202	0.000581	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Fluorouracil—skin cancer	0.000202	0.000581	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Fluorouracil—skin cancer	0.000202	0.000581	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Docetaxel—skin cancer	0.000201	0.00058	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Docetaxel—skin cancer	0.000201	0.000578	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Fluorouracil—skin cancer	0.0002	0.000577	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Dactinomycin—skin cancer	0.000199	0.000574	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000199	0.000574	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Temozolomide—skin cancer	0.000198	0.00057	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Dactinomycin—skin cancer	0.000198	0.00057	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Fluorouracil—skin cancer	0.000198	0.000569	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Fluorouracil—skin cancer	0.000197	0.000569	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Docetaxel—skin cancer	0.000197	0.000568	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Fluorouracil—skin cancer	0.000197	0.000567	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Temozolomide—skin cancer	0.000197	0.000566	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Temozolomide—skin cancer	0.000195	0.000562	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Temozolomide—skin cancer	0.000195	0.00056	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Docetaxel—skin cancer	0.000194	0.000558	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Temozolomide—skin cancer	0.000193	0.000555	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Fluorouracil—skin cancer	0.000192	0.000553	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Docetaxel—skin cancer	0.000191	0.000551	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Dactinomycin—skin cancer	0.000191	0.000551	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Dactinomycin—skin cancer	0.000191	0.000551	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Bleomycin—skin cancer	0.000191	0.00055	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Temozolomide—skin cancer	0.00019	0.000548	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Docetaxel—skin cancer	0.00019	0.000547	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Temozolomide—skin cancer	0.000189	0.000544	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Temozolomide—skin cancer	0.000189	0.000543	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Fluorouracil—skin cancer	0.000188	0.000543	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Temozolomide—skin cancer	0.000187	0.000539	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Bleomycin—skin cancer	0.000186	0.000536	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Docetaxel—skin cancer	0.000186	0.000535	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Docetaxel—skin cancer	0.000185	0.000533	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Docetaxel—skin cancer	0.000185	0.000532	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Docetaxel—skin cancer	0.000184	0.000529	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000184	0.000529	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Bleomycin—skin cancer	0.000184	0.000529	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Fluorouracil—skin cancer	0.000182	0.000525	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Fluorouracil—skin cancer	0.000181	0.000521	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Docetaxel—skin cancer	0.000181	0.000521	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Temozolomide—skin cancer	0.00018	0.000519	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Fluorouracil—skin cancer	0.00018	0.000518	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Docetaxel—skin cancer	0.000179	0.000517	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Fluorouracil—skin cancer	0.000179	0.000516	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Temozolomide—skin cancer	0.000179	0.000515	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Docetaxel—skin cancer	0.000178	0.000513	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Docetaxel—skin cancer	0.000178	0.000513	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Dactinomycin—skin cancer	0.000178	0.000513	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Fluorouracil—skin cancer	0.000177	0.000511	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—FOXO4—skin cancer	0.000177	0.00885	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—MSH2—skin cancer	0.000177	0.00884	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Fluorouracil—skin cancer	0.000175	0.000505	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Docetaxel—skin cancer	0.000175	0.000503	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000175	0.00873	CbGpPWpGaD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000174	0.000501	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Temozolomide—skin cancer	0.000174	0.000501	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Dactinomycin—skin cancer	0.000174	0.0005	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—CDK4—skin cancer	0.000174	0.00868	CbGpPWpGaD
Medroxyprogesterone Acetate—Body temperature increased—Temozolomide—skin cancer	0.000173	0.000498	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Temozolomide—skin cancer	0.000173	0.000498	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Docetaxel—skin cancer	0.000172	0.000497	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—FOXO4—skin cancer	0.000172	0.00859	CbGpPWpGaD
Medroxyprogesterone Acetate—Muscle spasms—Docetaxel—skin cancer	0.000171	0.000494	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO4—skin cancer	0.000169	0.00846	CbGpPWpGaD
Medroxyprogesterone Acetate—Feeling abnormal—Fluorouracil—skin cancer	0.000166	0.000478	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Dactinomycin—skin cancer	0.000166	0.000477	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Bleomycin—skin cancer	0.000165	0.000475	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Docetaxel—skin cancer	0.000165	0.000475	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Bleomycin—skin cancer	0.000164	0.000471	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Bleomycin—skin cancer	0.000163	0.000471	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Temozolomide—skin cancer	0.000161	0.000464	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Fluorouracil—skin cancer	0.00016	0.000461	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Docetaxel—skin cancer	0.00016	0.00046	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Fluorouracil—skin cancer	0.000159	0.000459	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Docetaxel—skin cancer	0.000158	0.000454	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PLIN2—skin cancer	0.000157	0.00788	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Temozolomide—skin cancer	0.000157	0.000452	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Docetaxel—skin cancer	0.000157	0.000451	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Temozolomide—skin cancer	0.000155	0.000446	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Docetaxel—skin cancer	0.000155	0.000445	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Bleomycin—skin cancer	0.000154	0.000444	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Dactinomycin—skin cancer	0.000154	0.000443	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Dactinomycin—skin cancer	0.000153	0.000439	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Docetaxel—skin cancer	0.000152	0.000437	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Docetaxel—skin cancer	0.000152	0.000437	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Docetaxel—skin cancer	0.000152	0.000437	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000151	0.000434	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—skin cancer	0.00015	0.00752	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Temozolomide—skin cancer	0.00015	0.000431	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Fluorouracil—skin cancer	0.000149	0.000428	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Docetaxel—skin cancer	0.000148	0.000428	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Docetaxel—skin cancer	0.000147	0.000423	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Docetaxel—skin cancer	0.000146	0.000419	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Docetaxel—skin cancer	0.000146	0.000419	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Temozolomide—skin cancer	0.000145	0.000417	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Docetaxel—skin cancer	0.000145	0.000416	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Dactinomycin—skin cancer	0.000144	0.000414	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—skin cancer	0.000144	0.00718	CbGpPWpGaD
Medroxyprogesterone Acetate—Shock—Docetaxel—skin cancer	0.000143	0.000412	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Docetaxel—skin cancer	0.000143	0.000411	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Fluorouracil—skin cancer	0.000143	0.000411	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Docetaxel—skin cancer	0.000142	0.00041	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Docetaxel—skin cancer	0.000142	0.000409	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—RHOU—skin cancer	0.000142	0.00708	CbGpPWpGaD
Medroxyprogesterone Acetate—Skin disorder—Docetaxel—skin cancer	0.000141	0.000407	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Temozolomide—skin cancer	0.000139	0.000401	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Docetaxel—skin cancer	0.000139	0.000399	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Temozolomide—skin cancer	0.000138	0.000397	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Fluorouracil—skin cancer	0.000138	0.000397	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Temozolomide—skin cancer	0.000138	0.000397	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000138	0.00689	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Temozolomide—skin cancer	0.000137	0.000395	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—MSH2—skin cancer	0.000136	0.00681	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypotension—Docetaxel—skin cancer	0.000136	0.000392	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Fluorouracil—skin cancer	0.000133	0.000384	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—skin cancer	0.000133	0.00667	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—CDKN2A—skin cancer	0.000133	0.00664	CbGpPWpGaD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000133	0.000382	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—CDK4—skin cancer	0.000132	0.00662	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—TERT—skin cancer	0.000132	0.0066	CbGpPWpGaD
Medroxyprogesterone Acetate—Insomnia—Docetaxel—skin cancer	0.000132	0.000379	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Docetaxel—skin cancer	0.000131	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.00013	0.00653	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Temozolomide—skin cancer	0.00013	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Docetaxel—skin cancer	0.00013	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Docetaxel—skin cancer	0.000129	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Fluorouracil—skin cancer	0.000128	0.000369	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Docetaxel—skin cancer	0.000128	0.000369	CcSEcCtD
Medroxyprogesterone Acetate—AR—Coregulation of Androgen receptor activity—CDKN2A—skin cancer	0.000128	0.00639	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Fluorouracil—skin cancer	0.000127	0.000366	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Fluorouracil—skin cancer	0.000127	0.000366	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—CSPG4—skin cancer	0.000127	0.00635	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Docetaxel—skin cancer	0.000127	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Fluorouracil—skin cancer	0.000126	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Docetaxel—skin cancer	0.000126	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Docetaxel—skin cancer	0.000125	0.000361	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Docetaxel—skin cancer	0.000124	0.000358	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Docetaxel—skin cancer	0.00012	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Fluorouracil—skin cancer	0.00012	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Docetaxel—skin cancer	0.000119	0.000343	CcSEcCtD
Medroxyprogesterone Acetate—AR—Nongenotropic Androgen signaling—HRAS—skin cancer	0.000117	0.00585	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.000115	0.00577	CbGpPWpGaD
Medroxyprogesterone Acetate—Body temperature increased—Docetaxel—skin cancer	0.000115	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Docetaxel—skin cancer	0.000115	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—RHOU—skin cancer	0.000112	0.00559	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Transcription factor regulation in adipogenesis—IL6—skin cancer	0.000112	0.00559	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Docetaxel—skin cancer	0.000107	0.000309	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000106	0.00531	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Docetaxel—skin cancer	0.000104	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—FOXO4—skin cancer	0.000104	0.00519	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Docetaxel—skin cancer	0.000103	0.000297	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—skin cancer	0.000103	0.00515	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—CDK4—skin cancer	0.000103	0.00514	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—skin cancer	0.000101	0.00506	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000101	0.00503	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Docetaxel—skin cancer	9.96e-05	0.000287	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—NRAS—skin cancer	9.84e-05	0.00492	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Docetaxel—skin cancer	9.62e-05	0.000277	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Docetaxel—skin cancer	9.25e-05	0.000266	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Docetaxel—skin cancer	9.18e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Docetaxel—skin cancer	9.17e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Docetaxel—skin cancer	9.12e-05	0.000263	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—NRAS—skin cancer	8.97e-05	0.00449	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—CDKN2A—skin cancer	8.82e-05	0.00441	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—CDKN2A—skin cancer	8.68e-05	0.00434	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Docetaxel—skin cancer	8.64e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—ENO2—skin cancer	8.62e-05	0.00431	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	8.54e-05	0.00427	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—KRAS—skin cancer	8.47e-05	0.00424	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CDK4—skin cancer	8.09e-05	0.00405	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PLIN2—skin cancer	7.77e-05	0.00389	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—KRAS—skin cancer	7.72e-05	0.00386	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CSPG4—skin cancer	7.48e-05	0.00374	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—TP53—skin cancer	7.24e-05	0.00363	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—HRAS—skin cancer	7.2e-05	0.0036	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—BRAF—skin cancer	7.16e-05	0.00358	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PTCH2—skin cancer	6.91e-05	0.00346	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.74e-05	0.00337	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	6.71e-05	0.00336	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	6.56e-05	0.00329	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RHOU—skin cancer	6.55e-05	0.00328	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Arachidonic acid metabolism—PTGS2—skin cancer	6.55e-05	0.00328	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CSPG4—skin cancer	6.27e-05	0.00314	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CDK4—skin cancer	6.24e-05	0.00312	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—NRAS—skin cancer	5.88e-05	0.00294	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—BRAF—skin cancer	5.52e-05	0.00276	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTCH2—skin cancer	5.45e-05	0.00273	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	5.33e-05	0.00267	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—GLI2—skin cancer	5.24e-05	0.00262	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	5.17e-05	0.00259	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—IL6—skin cancer	5.15e-05	0.00258	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—SHH—skin cancer	5.09e-05	0.00254	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ENO2—skin cancer	5.09e-05	0.00254	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—KRAS—skin cancer	5.06e-05	0.00253	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—ERCC2—skin cancer	5.01e-05	0.00251	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MC1R—skin cancer	5e-05	0.0025	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—GLI1—skin cancer	4.93e-05	0.00246	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.91e-05	0.00246	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—TP53—skin cancer	4.91e-05	0.00246	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—TP53—skin cancer	4.83e-05	0.00242	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	4.79e-05	0.0024	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SUFU—skin cancer	4.67e-05	0.00234	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—IL6—skin cancer	4.49e-05	0.00225	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—HRAS—skin cancer	4.44e-05	0.00222	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—IL6—skin cancer	4.42e-05	0.00221	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—HRAS—skin cancer	4.3e-05	0.00215	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—ENO2—skin cancer	4.26e-05	0.00213	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—skin cancer	4.26e-05	0.00213	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—FOXO4—skin cancer	4.15e-05	0.00207	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—GLI2—skin cancer	4.13e-05	0.00207	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—IL6—skin cancer	4.11e-05	0.00206	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	3.99e-05	0.002	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MC1R—skin cancer	3.94e-05	0.00197	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—IL6—skin cancer	3.9e-05	0.00195	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—GLI1—skin cancer	3.89e-05	0.00194	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—KRAS—skin cancer	3.87e-05	0.00194	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	3.69e-05	0.00185	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SUFU—skin cancer	3.68e-05	0.00184	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SHH—skin cancer	3.56e-05	0.00178	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—RASA1—skin cancer	3.54e-05	0.00177	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—NRAS—skin cancer	3.45e-05	0.00173	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—TP53—skin cancer	3.44e-05	0.00172	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SMO—skin cancer	3.38e-05	0.00169	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PTCH1—skin cancer	3.38e-05	0.00169	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.33e-05	0.00167	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PTGER4—skin cancer	3.29e-05	0.00164	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.21e-05	0.00161	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTCH2—skin cancer	3.2e-05	0.0016	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—IL6—skin cancer	3.07e-05	0.00154	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PTGS2—skin cancer	3e-05	0.0015	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—KRAS—skin cancer	2.98e-05	0.00149	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—KRAS—skin cancer	2.97e-05	0.00149	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ERCC2—skin cancer	2.95e-05	0.00148	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FOXO4—skin cancer	2.9e-05	0.00145	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.85e-05	0.00143	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SHH—skin cancer	2.81e-05	0.00141	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—RASA1—skin cancer	2.79e-05	0.0014	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—TERT—skin cancer	2.77e-05	0.00139	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—IL6—skin cancer	2.7e-05	0.00135	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SMO—skin cancer	2.66e-05	0.00133	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTCH1—skin cancer	2.66e-05	0.00133	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—skin cancer	2.65e-05	0.00133	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTGER4—skin cancer	2.59e-05	0.0013	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—HRAS—skin cancer	2.52e-05	0.00126	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—ERCC2—skin cancer	2.51e-05	0.00126	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—ERCC2—skin cancer	2.47e-05	0.00124	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.47e-05	0.00124	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GLI2—skin cancer	2.43e-05	0.00121	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—IL6—skin cancer	2.41e-05	0.00121	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—IL6—skin cancer	2.33e-05	0.00117	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MC1R—skin cancer	2.31e-05	0.00116	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FOXO4—skin cancer	2.29e-05	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GLI1—skin cancer	2.28e-05	0.00114	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.2e-05	0.0011	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—BRAF—skin cancer	2.19e-05	0.0011	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PLIN2—skin cancer	2.19e-05	0.00109	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SUFU—skin cancer	2.16e-05	0.00108	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TERT—skin cancer	1.94e-05	0.00097	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—ERCC2—skin cancer	1.91e-05	0.000957	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PLIN2—skin cancer	1.78e-05	0.00089	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTGS2—skin cancer	1.77e-05	0.000886	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CSPG4—skin cancer	1.76e-05	0.000881	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SHH—skin cancer	1.65e-05	0.000825	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RASA1—skin cancer	1.64e-05	0.00082	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTCH1—skin cancer	1.56e-05	0.000782	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SMO—skin cancer	1.56e-05	0.000782	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—BRAF—skin cancer	1.54e-05	0.000768	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TERT—skin cancer	1.53e-05	0.000765	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTGER4—skin cancer	1.52e-05	0.000761	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTGS2—skin cancer	1.48e-05	0.000742	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—ERCC2—skin cancer	1.47e-05	0.000737	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ERCC2—skin cancer	1.45e-05	0.000726	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CSPG4—skin cancer	1.43e-05	0.000717	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NRAS—skin cancer	1.38e-05	0.00069	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FOXO4—skin cancer	1.34e-05	0.000673	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—BRAF—skin cancer	1.21e-05	0.000606	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ENO2—skin cancer	1.2e-05	0.000599	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KRAS—skin cancer	1.19e-05	0.000594	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PLIN2—skin cancer	1.17e-05	0.000587	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HRAS—skin cancer	1.01e-05	0.000504	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ENO2—skin cancer	9.75e-06	0.000488	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NRAS—skin cancer	9.65e-06	0.000483	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IL6—skin cancer	9.65e-06	0.000483	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CSPG4—skin cancer	9.45e-06	0.000473	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.36e-06	0.000469	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TERT—skin cancer	8.98e-06	0.000449	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KRAS—skin cancer	8.31e-06	0.000416	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.62e-06	0.000381	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NRAS—skin cancer	7.61e-06	0.000381	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—skin cancer	7.38e-06	0.000369	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—BRAF—skin cancer	7.11e-06	0.000356	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HRAS—skin cancer	7.06e-06	0.000353	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ERCC2—skin cancer	6.96e-06	0.000348	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL6—skin cancer	6.76e-06	0.000338	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KRAS—skin cancer	6.55e-06	0.000328	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ENO2—skin cancer	6.43e-06	0.000322	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—skin cancer	5.82e-06	0.000291	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ERCC2—skin cancer	5.66e-06	0.000283	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HRAS—skin cancer	5.57e-06	0.000279	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL6—skin cancer	5.33e-06	0.000267	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NRAS—skin cancer	4.47e-06	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS2—skin cancer	4.17e-06	0.000209	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KRAS—skin cancer	3.85e-06	0.000192	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ERCC2—skin cancer	3.73e-06	0.000187	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—skin cancer	3.42e-06	0.000171	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS2—skin cancer	3.39e-06	0.00017	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HRAS—skin cancer	3.27e-06	0.000164	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL6—skin cancer	3.13e-06	0.000157	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS2—skin cancer	2.24e-06	0.000112	CbGpPWpGaD
